Image may be NSFW.
Clik here to view.
Amgen (NSDQ:AMGN) said today that it lowered the list prices of the drug-delivery devices for its cholesterol drug, Repatha, to $5,850 per year.
The Thousand Oaks, Calif.-based company touted the 60% discount as a way to boost patient affordability and accessibility.
Get the full story at our sister site, Drug Delivery Business News.
The post Amgen touts lowered prices for Repatha delivery devices appeared first on MassDevice.
